Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer
Go back to Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer| (NASDAQ: PPCB) | Delayed: 1.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.01 | 52 Week High | $ | |||
| Open | $1.02 | 52 Week Low | $ | |||
| Day High | $1.03 | P/E | N/A | |||
| Day Low | $1.00 | EPS | $ | |||
| Volume | 39,760 | |||||
